Nowadays approximately 80% of children and adolescents with acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) can be cured and become long-term survivors. Avascular osteonecroses (ON) appear as serious side-effect of antileukaemic treatment. Frequently ON are first diagnosed at higher and than irreversible stages (ARCO III, IV). At these advanced stages curative treatment options are not available. Hence ON are associated with considerable morbidity concerning pain and immobility and go along with long-term impairment of quality of life. Therefore early diagnosis of ON in the follow-up of children and young adults with ALL or LBL is a pressing object. Within the prospective multicentric observational OPAL-trial patients at risk (aged 10 years or older) treated according to the clinical trials ALL-BFM(Berlin-Frankfurt-Muenster Study Group), COALL or NHL (Non Hodgkin Lymphoma)-BFM in Germany should be examined with regard to the development of ON. By using a treatment associated, risk orientated assessment and examination incidence, symptoms and the clinical course of ON are investigated. The validity of MRI screening in the early diagnosis of ON in children and young adults is analysed. Systematical investigation of patients under antileukaemic treatment is intended to contribute to risk adapted diagnostic strategies and to serve as data base for the subsequent evaluation of preventive and interventional approaches for the treatment of ON. Long-term objective is the reduction of ON-associated morbidity.
Study Type
OBSERVATIONAL
Enrollment
400
Department of Paediatric and Adolescend Medicine, University Aachen
Aachen, Germany
RECRUITINGDepartment of Pediatrics, Haematology and Oncology, University Bonn
Bonn, Germany
RECRUITINGDepartment for Children and Adolescent Helth Chemnitz gGmbH
Chemnitz, Germany
RECRUITINGClinic of Pediatric and Adolescent Medicine, Vestische Caritas Clinic Datteln
Datteln, Germany
occurence of early ON stages
Calculation of the rate of by MRI detectable (still) asymptomatic patients with early ON stages (I and II) within the patients who develop symptomatic ON in the further course
Time frame: 6 years
ON incidence
Prospective evaluation of incidence of asymptomatic and symptomatic ON in children and adolescents with ALL or LBL
Time frame: 6 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Division of Pediatric Hematology and Oncology, University Children´s Hospital
Dresden, Germany
RECRUITINGClinic of Pediatric Oncology, Hematology and Clinical Immunology, Center for Child and Adolescent Health, Heinrich Heine University
Düsseldorf, Germany
RECRUITINGClinic of Pediatrics and Adolescent , Pediatric Hematology and Oncology
Erlangen, Germany
RECRUITINGDepartment of Pediatric-Oncology/-Hematology and clin. Immunology, University Medicine Essen
Essen, Germany
RECRUITINGDepartment of Pediatric Hematology, Oncology and Hemostaseology, Goethe-University, University Children's Hospital
Frankfurt am Main, Germany
RECRUITINGPediatric Hematology and Oncology, University Medicine Greifswald
Greifswald, Germany
RECRUITING...and 15 more locations